All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MLE-301
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: MLE-301
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2021
Details:
While MLE-301 was generally well-tolerated, the data do not support moving forward with its development in the target population of peri- and post-menopausal women, especially with the evolving dynamics of a highly competitive NK3R antagonist market.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MLE-301
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: MLE-301
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
The single ascending dose portion of the study will be conducted in healthy male volunteers, to determine the pharmacokinetics of MLE-301 and its pharmacodynamic profile as measured by reductions of biomarkers (luteinizing hormone, testosterone).
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
